The release of Phase III Stage 1 data for gotistobart (BNT316/ONC-392) at NACLC 2025 marks one of the most significant ...

Gilead Sciences subsidiary Kite and its partner Arcellx have announced new positive data from the pivotal iMMagine-1 Phase II ...

German biotech BioNTech USA-based OncoC4 yesterday presented data from the non-pivotal dose-confirmation stage of the global ...

Belgian biotech Galapagos reported new Phase II results for its fresh, memory-enriched CAR T candidate GLPG5101 in relapsed ...

Belgium’s UCB has presented positive efficacy and safety results from the GEMZ Phase III study investigating adjunctive ...

US rare disease drug developer Mirum Pharmaceuticals today announced its entry into a definitive agreement to acquire Bluejay ...

A German court has ordered Merck & Co (NYSE: MRK) to halt launch preparations for its new subcutaneous version of Keytruda ...

Dutch biotech Pan Cancer T has raised 10 million euros ($11 million) to advance its lead cell therapy, PCT1:CO-STIM, into a ...

Denmark-based clinical-stage techbio Evaxion Biotech, which is specializing in developing AI-Immunology powered vaccines, ...

Shanghai-based biotech OTR Therapeutics has emerged from stealth and announced the successful completion of a $100 million ...

Swiss incubator Xlife Sciences today announced that Mexico-based Grupo Landsteiner has signed a binding framework to acquire ...

The USA’s immunization advisers have voted to shift long-standing guidance on hepatitis B vaccination for newborns, ...